Biopolym. Cell. 2014; 30(1):47-53.
Biomedicine
T-138C polymorphism of MGP gene is associated with blood plasma cholesterol levels but not related to other risk factors of atherosclerosis in patients with ischemic stroke
1Garbuzova V. Yu., 2Polonikov A. V., 1Ataman Y. A., 1Mychaylova T. I., 1Obukhova O. A., 1Matlaj O. I., 1Ataman A. V.
  1. Sumy State University
    2, Rymskogo-Korsakova., Sumy, Ukraine, 40007
  2. Kursk State Medical University
    3, Karl Marx Str., Kursk, Russian Federation, 305041

Abstract

Aim. To analyse the association of MGP gene promotor T-138C polymorphism (rs1800802) with known risk factors of atherosclerosis and its complications (hypercholesterolemia, hypertension, high body mass index, diabetes, smoking, hypercoagulability) in patients with ischemic stroke (IS) of atherothrombotic origin. Methods. Venous blood of 170 IS patients was used for genotyping. The MGP gene polymorphism was examined by PCRRFLP methodology. Results. The carriers of a minor allele (T/C + C/C) had higher total cholesterol (5.4 ± 0.19 vs 4.8 ± 0.15 mmol/l, P = 0.025) and LDL-cholesterol concentrations (3.6 ± 0.17 vs 3.0 ± 0.14 mmol/l, P = 0.008), and lower HDL-cholesterol level (0.96 ± 0,04 vs 1.1 ± 0.03 mmol/l, P = 0.029) in blood plasma than the major allele homozygotes (T/T). Conclusions. It has been found no association between T-138C polymorphism of MGP gene and known risk factors for atherosclerosis and its complications (BMI, hypertension, diabetes, smoking, hypercoagulability) in patients with IS from the northeastern region of Ukraine. IS patients with the minor allele have more pronounced atherogenic changes in blood plasma lipoproteins as compared with the major allele homozygotes.
Keywords: arterial calcification, ischemic stroke, matrix Gla protein, single nucleotide polymorphism

References

[1] Shanahan CM, Proudfoot D, Tyson KL, Cary NRB, Edmonds M, Weissberg PL. Expression of mineralisation-regulating proteins in association with human vascular calcification. Z Kardiol. 2000; 89(Suppl. 2):63–8.
[2] Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G. Spontaneous calcification of arteries and cartilage in mice lacking matrix Gla protein. Nature. 1997; 386(6620):78–81.
[3] Proudfoot D, Skepper JN, Shanahan CM, Weissberg PL. Calcification of human vascular cells in vitro is correlated with high levels of matrix Gla protein and low levels of osteopontin expression. Arterioscler Thromb Vasc Biol. 1998; 18(3):379–88.
[4] Dhore CR, Cleutjens JP, Lutgens E, Cleutjens KB, Geusens PP, Kitslaar PJ, Tordoir JH, Spronk HM, Vermeer C, Daemen MJ. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2003; 21(12):1998–2003.
[5] Doherty TM, Fitzpatrick LA, Inoue D, Qiao JH, Fishbein MC, Detrano RC, Shah PK, Rajavashisth TB. Molecular, endocrine, and genetic mechanisms of arterial calcification. Endocr Rev. 2004; 25(4):629–72.
[6] Shearer MJ. Role of vitamin K and Gla proteins in the pathophysiology of osteoporosis and vascular calcification. Curr Opin Clin Nutr Metab Care. 2000; 3(6):433–38.
[7] Murshed M, Schinke T, McKee MD, Karsenty G. Extracellular matrix mineralization is regulated locally: different roles of two gla-containing proteins. J Cell Biol. 2004; 165(5):625–30.
[8] Cancela L, Hsieh CL, Francke U, Price PA. Molecular structure, chromosome assignment, and promoter organization of the human matrix Gla protein gene. J Biol Chem. 1990; 265(25):15040–8.
[9] Brancaccio D, Biondi ML, Gallieni M, Turri O, Galassi A, Cecchini F, Russo D, Andreucci V, Cozzolino M. Matrix GLA protein gene polymorphisms: clinical correlates and cardiovascular mortality in chronic kidney disease patients. Am J Nephrol. 2005; 25 (6):548–52.
[10] Crosier MD, Booth SL, Peter I, Dawson-Hughes B, Price PA, O'Donnell CJ, Hoffmann U, Wiilliamson MK, Ordovas JM. Matrix Gla protein polymorphisms are associated with coronary artery calcification in men. J Nutr Sci Vitaminol (Tokyo). 2009; 55 (1):59–65.
[11] Farzaneh-Far A, Davies JD, Braam LA, Spronk HM, Proudfoot D, Chan SW, O'Shaughnessy KM, Weissberg PL, Vermeer C, Shanaham CM. A polymorphism of the human matrix gammacarboxyglutamic acid protein promoter alters binding of an activating protein-1 complex and is associated with altered transcription and serum levels. J Biol Chem. 2001; 276(35):32466–73.
[12] Hernandez-Pacheco G, Murguia LE, Rodriguez-Perez JM, Fragoso JM, Perez-Vielma N, Martinez-Rodriguez N, Granados J, Vargas-Alarcon G. Matrix gamma-carboxyglutamic acid protein (MGP) G-7A and T-138C gene polymorphisms in Indian (Mayo and Teenek) and Mestizo populations from Mexico. Hum Biol. 2005; 77(3):385–91.
[13] Herrmann SM, Whatling C, Brand E, Nikaud V, Gariepy J, Simon A, Evans A, Ruidavets LB, Arveiler D, Luc G, Tiret L, Henney A, Cambien F. Polymorphisms of the human matrix gla protein (MGP) gene, vascular calcification, and myocardial infarction. Arterioscler Thromb Vasc Biol. 2000; 20(11):2386–93.
[14] Kobayashi N, Kitazawa R, Maeda S, Schurgers LJ, Kitazawa S. T-138C polymorphism of matrix gla protein promoter alters its expression but is not directly associated with atherosclerotic vascular calcification. Kobe J Med Sci. 2004; 50(3–4):69–81.
[15] Taylor BC, Schreiner PJ, Doherty TM, Fornage M, Carr JJ, Sidney S. Matrix Gla protein and osteopontin genetic associations with coronary artery calcification and bone density: the CARDIA study. Hum Genet. 2005; 116(6):525–8.
[16] Bos D, Ikram MA, Elias-Smale SE, Krestin GP, Hofman A, Witteman JC, van der Lugt A, Vernooij MW. Calcification in major vessel beds relates to vascular brain disease. Arterioscler Thromb Vasc Biol. 2011; 31(10):2331–7.
[17] Ataman AV, Garbusova VY, Ataman YA, Matlaj OI, Obuchova OA. Investigation of the MGP promoter and exon 4 polymorphisms in patients with ischemic stroke in the Ukrainian population. J Cell Mol Biol. 2012; 10(1):19–26.
[18] Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke. Treatment Stroke. 1993; 24(1):35–41.
[19] Abedin M, Tintut Y, Demer LL. Vascular calcification. Mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol. 2004; 24(7):1161–70.
[20] Atkinson J. Age-related medial elastocalcinosis in arteries: mechanisms, animal models, and physiological consequences. J Appl Physiol. 2008; 105(5):1643–51.
[21] Guzman RJ. Clinical, cellular, and molecular aspects of arterial calcification. J Vasc Surg. 2007; 45(Suppl. A):A57–A63.
[22] Braam LA, Dissel P, Gijsbers BL, Spronk HMH, Hamulyak K, Soute B. AM, Debie W, Vermeer C. Assay for human matrix gla protein in serum: potential applications in the cardiovascular field. Arterioscler Thromb Vasc Biol. 2000; 20(5):1257–61.
[23] Jono S, Vermeer C, Dissel P, Hasegava K, Shioi A, Taniwaki H, Kizu A, Nishizawa Y, Saito S. Matrix Gla protein is associated with coronary artery calcification as assessed by electron-beam computed tomography. Thromb Haemost. 2004; 91(4):790–4.
[24] O'Donnell CJ, Kyla Shea M, Price PA, Gagnon DR, Wilson PWF, Larson MG, Kiel DP, Hoffmann U, Ferencik M, Clouse ME, Williamson MK, Cupples LA, Dawson-Hughes B, Booth SL. Matrix Gla protein is associated with risk factors for atherosclerosis but not with coronary artery calcification. Arterioscler Thromb Vasc Biol. 2006; 26(12):2769–74.
[25] Acar A, Cevik MU, Arikanoglu A, Evliyaoglu O, Basarili MK, Uzar E, Ekici F, Yucel Y, Tasdemir N. Serum levels of calcification inhibitors in patients with intracerebral hemorrhage. Int J Neurosci. 2012; 122(5):227–32.
[26] del Rio-Espinola A, Fernandez-Cadenas I, Rubiera M, Quintana M, Domingues-Montanari S, Mendioroz M, FernandezMorales J, Giralt D, Molina CA, Alvarez-Sabin J, Montaner J. CD40-1 C > T polymorphism (rs1883832) is associated with brain vessel reocclusion after fibrinolysis in ischemic stroke. Pharmacogenomics. 2010; 11(6):763–72.